CHR. OLESEN PHARMACEUTICALS A/S
CVR number: 32090168
Jægersborg Alle 164, 2820 Gentofte
Income statement (kEUR)
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | 467.86 | 1 069.17 | 1 026.37 | 740.31 | 1 215.29 |
| Employee benefit expenses | - 222.53 | - 271.56 | - 307.34 | - 294.29 | - 474.81 |
| Total depreciation | -40.00 | -40.00 | -40.00 | -40.02 | |
| EBIT | 205.34 | 757.62 | 679.04 | 406.00 | 740.48 |
| Other financial income | 44.03 | 34.20 | 82.07 | 67.19 | 114.88 |
| Other financial expenses | - 105.89 | - 166.79 | - 176.77 | - 151.13 | - 257.99 |
| Net income from associates (fin.) | -14.50 | -12.18 | |||
| Pre-tax profit | 128.97 | 612.86 | 584.34 | 322.06 | 597.37 |
| Income taxes | -33.14 | - 137.95 | - 129.57 | -70.95 | - 132.13 |
| Net earnings | 95.83 | 474.91 | 454.76 | 251.10 | 465.24 |
Assets (kEUR)
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Machinery and equipment | 120.01 | 80.02 | 40.02 | ||
| Tangible assets total | 120.01 | 80.02 | 40.02 | ||
| Investments total | |||||
| Long term receivables total | |||||
| Finished products/goods | 3 798.16 | 2 452.25 | 3 156.88 | 4 368.41 | 4 546.43 |
| Inventories total | 3 798.16 | 2 452.25 | 3 156.88 | 4 368.41 | 4 546.43 |
| Current trade debtors | 1 748.18 | 2 994.34 | 2 296.56 | 2 465.14 | 2 575.46 |
| Current amounts owed by group member comp. | 1 186.93 | 2 760.81 | 3 890.49 | 6 088.35 | 7 759.58 |
| Prepayments and accrued income | 23.23 | 0.18 | 2.62 | ||
| Current other receivables | 14.44 | 77.42 | 25.77 | 24.22 | |
| Current deferred tax assets | 3.77 | 9.45 | 9.45 | ||
| Short term receivables total | 2 949.56 | 5 855.79 | 6 216.59 | 8 587.35 | 10 347.11 |
| Cash and bank deposits | 0.06 | 0.30 | 0.06 | 2.35 | 92.43 |
| Cash and cash equivalents | 0.06 | 0.30 | 0.06 | 2.35 | 92.43 |
| Balance sheet total (assets) | 6 867.79 | 8 388.36 | 9 413.55 | 12 958.11 | 14 985.98 |
Equity and liabilities (kEUR)
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Share capital | 79.17 | 79.17 | 79.17 | 79.17 | 79.17 |
| Retained earnings | - 205.50 | - 109.67 | 65.24 | 520.00 | 771.10 |
| Profit of the financial year | 95.83 | 474.91 | 454.76 | 251.10 | 465.24 |
| Shareholders equity total | -30.50 | 444.41 | 599.17 | 850.27 | 1 315.51 |
| Provisions | 11.13 | 6.70 | |||
| Non-current liabilities total | |||||
| Current loans from credit institutions | 5 302.23 | 6 303.23 | 7 098.83 | 10 217.41 | 10 843.99 |
| Current trade creditors | 1 427.03 | 1 118.08 | 1 120.37 | 775.01 | 1 621.55 |
| Current owed to group member | 63.94 | 220.64 | 285.76 | 881.64 | 771.03 |
| Short-term deferred tax liabilities | 76.89 | 217.68 | 275.60 | 211.03 | 343.15 |
| Other non-interest bearing current liabilities | 17.08 | 77.62 | 33.83 | 22.75 | 90.75 |
| Current liabilities total | 6 887.17 | 7 937.25 | 8 814.38 | 12 107.84 | 13 670.47 |
| Balance sheet total (liabilities) | 6 867.79 | 8 388.36 | 9 413.55 | 12 958.11 | 14 985.98 |
Try the full version of our system for free
Create your own estimates for any company
Valuation analysis
See instructions
... and more!
No registration needed.